Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
3
43%
Ph phase_1
2
29%
Ph phase_2
1
14%
Ph early_phase_1
1
14%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
Phase 21 (14.3%)
N/A3 (42.9%)

Trials by Status

completed457%
withdrawn229%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

NCT03199274
completednot_applicable

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

NCT03318380
completedphase_1

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

NCT03045497
withdrawnearly_phase_1

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery

NCT02671552
completednot_applicable

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

NCT01631318
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03199274Phase 2

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Completed
NCT03318380Not Applicable

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

Completed
NCT03045497Phase 1

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

Completed
NCT02671552Early Phase 1

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery

Withdrawn
NCT01631318Not Applicable

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Completed
NCT03300401Not Applicable

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn
NCT02067884Phase 1

Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery

Terminated

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7